Stockscreener 앱 받기
1.10
1.85%
0.02
시장 영업 전:
1.14
0.04
+3.64%
전일 마감가:
$1.08
열려 있는:
$1.08
하루 거래량:
397.68K
Relative Volume:
1.33
시가총액:
$52.02M
수익:
$928.00K
순이익/손실:
$-11.11M
주가수익비율:
-3.0942
EPS:
-0.3555
순현금흐름:
$-10.40M
1주 성능:
+6.80%
1개월 성능:
+20.88%
6개월 성능:
-5.98%
1년 성능:
+3.77%
1일 변동 폭
$1.0601
$1.14
1주일 범위
$0.9701
$1.19
52주 변동 폭
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.10 | 52.02M | 928.00K | -11.11M | -10.40M | -0.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx CFO voll acquires shares and warrants in RNXT By Investing.com - Investing.com Australia
Laurence Marton buys RenovoRx stock and warrants for $10,000 By Investing.com - Investing.com South Africa
Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock - Investing.com
Laurence Marton buys RenovoRx stock and warrants for $10,000 - Investing.com
RenovoRx (RNXT) CEO’s family trust buys shares and new warrants - Stock Titan
RenovoRx (RNXT) director adds $10K via rollover IRA private deal - Stock Titan
The most innovative medical device companies of 2026 - Fast Company
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - Investing News Network
RenovoRx Secures $10 Million Oversubscribed Private Placement to Accelerate RenovoCath Commercialization and Advance Phase III Pancreatic Cancer Trial - Minichart
Trend Recap: Can RenovoRx Inc expand its profit margins2026 Year in Review & Growth Focused Entry Reports - baoquankhu1.vn
RenovoRx Raises $10 Million in Oversubscribed Private Placement - TipRanks
RenovoRx Raises ~$10 Million in Private Placement; Sells Stock and Warrants at $0.938 Per Share - TradingView
RenovoRx (Nasdaq: RNXT) nets $10M private placement with milestone warrants - Stock Titan
RenovoRx (RNXT) Expected to Announce Quarterly Earnings on Monday - Defense World
Panic Selling: How does RenovoRx Inc perform in inflationary periods2026 Geopolitical Influence & Entry and Exit Point Strategies - baoquankhu1.vn
Downgrade Watch: Can RenovoRx Inc deliver alphaWeekly Trade Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET - Investing News Network
Draganfly to Host Shareholder Update Call on March 24, 2026 - weeklyvoice.com
RenovoRx March 30 call to cover 2025 results, Phase III trial timing - Stock Titan
RenovoRx, Inc. announced that it has received $10 million in funding from Transcend Partners LLC, Aigh Capital Management, LLC, Bleichroeder LP, Pathfinder Asset Management Limited - marketscreener.com
Aug Wrap: Can KLRS outperform under higher oil prices2026 Final Week & Weekly Breakout Watchlists - baoquankhu1.vn
Risk Off: Will cbdMD Inc outperform its industry peers2026 Chart Watch & High Yield Stock Recommendations - baoquankhu1.vn
RenovoRx raises $10M in oversubscribed private placement By Investing.com - Investing.com Australia
Support Test: Is RenovoRx Inc exposed to political riskEarnings Performance Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
RenovoRx Announces $10 Million at Market Private Placement - Investing News Network
RenovoRx prices 10.6M shares at 93.8c in private placement - TipRanks
RenovoRx, Inc. announced that it expects to receive $10 million in funding - marketscreener.com
RenovoRx announces $10 million private placement - MSN
RenovoRx raises $10M in oversubscribed private placement - Investing.com
RenovoRx announces $10 million at market Private Placement - marketscreener.com
Renovorx Announces $10 Million At Market Private Placement - TradingView
$10M investor bet on RenovoRx cancer device and trial push - Stock Titan
Aug Fed Impact: Is RenovoRx Inc a defensive stock2026 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn
RNXT Should I Buy - Intellectia AI
Gains Recap: What hedge funds are buying Arko CorpRate Cut & AI Forecast Swing Trade Picks - baoquankhu1.vn
Returns Recap: Can RenovoRx Inc expand its profit margins2026 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
What dividend safety score for RenovoRx Inc. stockEarnings Recap Report & Real-Time Volume Surge Alerts - Naître et grandir
Market Review: How much upside does RenovoRx Inc have2025 Technical Patterns & Growth Focused Entry Reports - baoquankhu1.vn
Insider Buy: Is RenovoRx Inc stock a value trapJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Macro: What chart patterns are forming on RenovoRx IncRecession Risk & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Block Trades: Will RenovoRx Inc benefit from rate cuts2025 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Guidance Update: Is RenovoRx Inc stock overvalued or fairly pricedJuly 2025 Recap & AI Driven Price Predictions - baoquankhu1.vn
RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum - marketscreener.com
US Market Recap: Whats the outlook for RenovoRx Incs sectorM&A Rumor & AI Enhanced Trading Alerts - baoquankhu1.vn
RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Down 20.6% in February - Defense World
RenovoRx advances RenovoCath adoption at U.S. cancer centers - Yahoo Finance
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum - Investing News Network
After 700 cancer procedures, RenovoCath gets new doctor-led commercial push - Stock Titan
Targeted chemo delivery for pancreatic cancer to feature at 2026 SIR meeting - Stock Titan
RNXT PE Ratio & Valuation, Is RNXT Overvalued - Intellectia AI
RenovoRx (RNXT) Price Target Increased by 10.66% to 6.88 - Nasdaq
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):